Chicago, IL – March 25, 2009 - MagSense Life Sciences Inc, a leading developer of magnetic separation technologies, announced it is actively seeking licensing partners among biotechnology companies.
Because of unprecedented interest in their technology platforms and applications, MagSense has begun to explore licensing partnership opportunities for magnetic separation technologies.
The focus of MagSense will be on securing exclusive or non-exclusive licensing agreements with biotechnology firms. In addition to its technology platforms, the company is prepared to create an exchange of its extensive knowledge on superparamagnetic particle technologies and bioseparations applications.
MagSense has designed, manufactured, and marketed magnetic separation technologies that enable researchers to attain high-purity biomolecules through the application of magnetic separation technologies. These are highly reliable, convenient, and cost-effective alternatives to more traditional bioseparation methods.
According to MagSense scientists, the interest is clearly growing for bioseparation methods that save time and money, and the prospects are truly exciting. As the company evaluates potential partners, the goal will be to advance MagSense innovative magnetic technologies to an expanded global biotechnology stage.
Biotechnology firms interested in reviewing MagSense technologies and products are invited to visit www.MagSenseLifeSci.com
About MagSense Life Sciences
MagSense Life Sciences, Inc, has developed superparamagnetic microparticles with enhanced magnetic properties and uniformity – ideally suited for pharmaceutical, biotechnology, and diagnostics companies, as well as research centers and laboratories of academic, government, and private foundations. Superparamagnetic microparticle applications include affinity separations (such as, the isolation of nucleic acids, small peptides, proteins, and cells from blood, environmental samples, or fermentation broth); human diagnostics (such as biosensors in response to malicious, accidental, or natural biological threats); high throughput screenings for drug discovery; and life science research (such as, bioanalytical analyses, genetic engineering, and proteomics). For more information on licensing its technologies, visit www.magsenselifesci.com.